Additional Intraoperative Autologous-Derived Platelet-Rich Stroma to Transanal Flap Repair for the Treatment of Cryptoglandular Transsphincteric Fistulas in a Tertiary Referral Center: Long-Term Outcomes of a Prospective
Bak MTJ., Witjes CDM., Dwarkasing RS., Arkenbosch JHC., Schouten WR., van Veen JC.
Prospective Study with a reported sample of 43 on Autoimmune Research, published in Bioengineering (Basel) (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Bioengineering (Basel) (2025)
- Country
- Switzerland
- Reported sample size
- 43
- Source database
- PubMed
- PMID
- 40001625
- PMCID
- PMC11851975
- DOI
- 10.3390/bioengineering12020105
Abstract (original English)
Transanal advancement flap repair (TAFR) fails in approximately 30-40% of patients with a cryptoglandular transsphincteric fistula. An additional intraoperative injection of autologous platelet-rich stroma (PRS) with TAFR proved to be safe, feasible, and effective in the short term for the treatment of cryptoglandular transsphincteric fistula in a tertiary referral center. In this study, we assessed the long-term outcomes in patients with a cryptoglandular transsphincteric fistula who were treated with an additional intraoperative autologous PRS injection with TAFR (n = 43). The majority of the patients (88%) had a complex transsphincteric fistula (high transsphincteric and/or multiple side tracts) and underwent (one or more) fistula procedure(s) aimed at fistula repair (56%) before study inclusion. At a median follow-up time of 4.2 years [IQR 3.5-5.1], long-term primary clinical closure (i.e., clinical closure of the treated external fistula opening(s) after TAFR with additional PRS injection without the need for any re-interventions during long-term follow-up) was observed in 77% of the patients. Subsequently, 94% of these patients also reached radiological healing (i.e., fibrotic fistula tract on MRI). Recurrence after clinical closure or radiological healing was observed in 9% and 5%. Unplanned re-interventions were performed in 12% of the patients for recurrent or residual
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ARandomized Controlled TrialPubMed
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
Randomized Controlled Trial with a reported sample of 283 on Autoimmune Research, published in Gastroenterology (2026) — summary generated from the PubMed abstract.
- 2026
- n = 283
Gastroenterology3 citations - Level ASystematic ReviewEurope PMC
Intraoperative Autologous Adipose-Derived Therapies and PRP as Add-On in the Surgical Treatment of Cryptoglandular and Crohn's Disease-Related Perianal Fistula-A Systematic Review
Systematic Review with a reported sample of 1017 on Autoimmune Research, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 1017
Bioengineering (Basel) - Level ASystematic ReviewEurope PMC
Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies
Systematic Review on Skin Aging, Chronic Inflammation, Autoimmune Research, published in Front Physiol (2026) — summary generated from the PubMed abstract.
- 2026
Front Physiol - Level ASystematic ReviewEurope PMC
Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions
Systematic Review on Autoimmune Research, published in World J Gastrointest Pharmacol Ther (2026) — summary generated from the PubMed abstract.
- 2026
World J Gastrointest Pharmacol Ther - Level ASystematic ReviewEurope PMC
Management of Oro-Antral Communication: A Systemic Review of Diagnostic and Therapeutic Strategies
Systematic Review on Autoimmune Research, published in Diagnostics (Basel) (2025) — summary generated from the PubMed abstract.
- 2025
Diagnostics (Basel)5 citations